杭州天晟泰丰药业

Hangzhou Tiansheng Taifeng Pharmaceutical is a clinical-stage biopharmaceutical company based in Hangzhou, China, specializing in the development of innovative therapies for metabolic diseases. The company's research focuses on multi-target incretin mimetics, including dual and triple agonists that target the GLP-1, GIP, and glucagon receptors. Its lead candidate, TST002, is a long-acting GLP-1/GIP receptor dual agonist currently undergoing Phase 1 clinical trials for the treatment of type 2 diabetes and obesity. Tiansheng Taifeng aims to provide next-generation metabolic treatments with improved efficacy and patient compliance. The company is supported by prominent venture capital firms and led by an experienced scientific management team.